Core Viewpoint - The orderly exit of institutional shareholders and the continuous increase in holdings by the controlling shareholder create a positive balance, optimizing the company's equity structure and enhancing market liquidity and capital stability, which is favorable for long-term investors [2] Group 1: Shareholder Actions - Guoshou Chengda plans to reduce its stake in Huaxi Biological by up to 2% of the total share capital between November 24, 2025, and February 20, 2026, as part of a normal exit within the fund's investment cycle [1] - After the reduction, Guoshou Chengda's shareholding will fall below 5%, no longer constituting a related party relationship, potentially allowing insurance and asset management funds to reinvest in Huaxi Biological [1] - The controlling shareholder, Huaxi Xinyu Investment Co., completed an increase in holdings by acquiring approximately 4.519 million shares for about 257 million yuan, raising its stake to 60.11% [1] Group 2: Business Strategy and Market Position - Huaxi Biological focuses on synthetic biology manufacturing, establishing an integrated business layout in the field of aging intervention, providing comprehensive solutions across pharmaceuticals, medical aesthetics, nutritional science, and dermatology [2] - The company is one of the few globally that has a comprehensive layout in the ECM (extracellular matrix) field, with a core research direction centered on the overall synergy of ECM key substances [2] - Huaxi Biological's growth stems from its ability to integrate various scientific dimensions, forming a complete layout in life-active substances, medical aesthetics, functional skincare, and oral nutrition [3] Group 3: Innovation and Development - The company exemplifies the transition of Chinese manufacturing enterprises towards foundational research and brand transformation, leveraging technological innovation to drive industry iteration [4] - Huaxi Biological has become a global leader in hyaluronic acid production, transitioning from animal extraction to microbial fermentation, significantly reducing costs while improving quality and stability [4] - The profits generated are reinvested into foundational and applied research, opening doors to cell biology and glycoscience, and positioning the company for success in technological innovation and brand building [4]

公告显示，国寿成达直接持有华熙生物股份数量为2893.65万股，占华熙生物总股本的6.01%。 北京商报讯（记者 丁宁）11月4日晚间，华熙生物（688363）发布公告称，公司股东国寿成达（上海） 健康产业股权投资中心（有限合伙）（以下简称"国寿成达"）计划根据市场情况通过集中竞价、大宗交 易的方式减持其所持有的华熙生物股份合计不超过963.36万股，拟减持股份数量占华熙生物总股本的比 例合计不超2%。 ...

Group 1: Industry Overview - The cosmetics retail sales in China grew by 3.9% year-on-year from January to September 2025, slightly underperforming the overall retail market by 0.6 percentage points, indicating a stable demand environment [4][14]. - Online platforms like Tmall and Douyin are experiencing a shift, with Tmall showing signs of recovery due to flash sales and member subsidies, while Douyin's growth has slightly slowed down [17][20]. - The demand for high-end and cost-effective products is increasing, while the mid-range segment is facing pressure due to a more conservative consumer environment [5][41]. Group 2: Competitive Landscape - The trend of domestic brands replacing foreign ones is slowing down, with leading foreign brands like L'Oréal and Estée Lauder showing signs of recovery in the Chinese market [23][24]. - The growth of domestic brands is becoming more differentiated, with some brands like Proya and Shiseido experiencing declines, while others like Youngor and Shanghai Jahwa continue to grow [23][24]. - The industry is witnessing an acceleration in the multi-brand matrix among leading companies, which is expected to increase market concentration [27][28]. Group 3: Key Companies - The report highlights several companies with strong growth potential, including Ruya Chen, Shumei Co., and Maogeping, which are expected to benefit from their brand strength and market positioning [3][54]. - Companies like Dekang Oral Care and Shanghai Jahwa are noted for their stable fundamentals and potential for marginal improvement, while others like Jinbo Biological and Huaxi Biological are anticipated to reach turning points [54]. - Ruya Chen's self-owned brand, Zhenjia, has shown significant growth, with a revenue increase of 345% year-on-year in Q3 2025, indicating strong brand development capabilities [60].

证券代码：688363 证券简称：华熙生物 公告编号：2025-043 华熙生物科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，国寿成达（上海）健康产业股权投资中心（有限合伙）（以 下简称"国寿成达"）直接持有华熙生物科技股份有限公司（以下简称"本公 司""华熙生物"）股份数量为 28,936,504 股，占华熙生物总股本的 6.01%。上 述股份全部为本公司首次公开发行前股份，并已于 2022 年 11 月 7 日起上市流通。 减持计划的主要内容 国寿成达计划根据市场情况通过集中竞价、大宗交易的方式减持其所持有的华熙 生物股份合计不超过 9,633,564 股，拟减持股份数量占华熙生物总股本的比例合 计不超过 2.00%，其中以集中竞价方式减持比例不超过 1.00%，减持数量不超过 4,816,782 股，以大宗交易方式减持比例不超过 1.00%，减持数量不超过 4,816,782 股，减持期间为减持股份计划公告披 ...

Core Viewpoint - Guoshou Chengda plans to reduce its holdings in Huaxi Biological through centralized bidding and block trading, with a maximum reduction of 9.6336 million shares, accounting for no more than 2% of the company's total share capital [1] Group 1 - Guoshou Chengda's reduction plan involves a total of up to 9.6336 million shares [1] - The proposed reduction represents a maximum of 2% of Huaxi Biological's total share capital [1]

人民财讯11月4日电，华熙生物(688363)11月4日公告，公司持股6.01%的股东国寿成达计划根据市场情 况通过集中竞价、大宗交易的方式减持其所持有的公司股份合计不超过963.36万股，拟减持股份数量占 公司总股本的比例合计不超过2%。 ...

Core Viewpoint - Guoshou Chengda plans to reduce its holdings in Huaxi Biological by up to 9.6336 million shares, representing no more than 2% of the company's total share capital [1] Summary by Category - **Share Reduction Plan** - Guoshou Chengda intends to reduce its stake in Huaxi Biological through centralized bidding and block trading methods [1] - The total number of shares to be reduced is up to 9.6336 million [1] - The proposed reduction accounts for a maximum of 2% of the company's total share capital [1]

华熙生物公告，截至公告披露日，持股2893.65万股（占6.01%）的股东国寿成达拟自2025年11月26日至 2026年2月23日，通过集中竞价减持不超481.68万股（不超1.00%）及大宗交易减持不超481.68万股（不 超1.00%），合计不超963.36万股，减持比例不超2.00%。 ...

Group 1 - The medical beauty sector experienced a decline of 2.68% on November 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.74 (+0.27%), Huaxi Biological at 52.05 (-2.01%), Aimeike at 151.92 (-3.46%), and Jinbo Biological at 243.02 (-4.84%) [1] Group 2 - The medical beauty sector saw a net outflow of 101 million yuan from institutional investors, while retail investors had a net inflow of 79.55 million yuan [1] - The trading volume and turnover for key stocks included *ST Meigu with 140,600 shares traded and a turnover of 53.3 million yuan, Huaxi Biological with 29,200 shares and 153 million yuan, Aimeike with 43,500 shares and 669 million yuan, and Jinbo Biological with 15,400 shares and 378 million yuan [1]

格隆汇11月4日｜华熙生物(688363.SH)公告称，股东国寿成达（上海）健康产业股权投资中心（有限合 伙）计划通过集中竞价或大宗交易方式减持公司股份合计不超过963.36万股，占公司总股本比例不超过 2.00%，其中集中竞价减持不超过481.68万股，大宗交易减持不超过481.68万股。减持原因为自身资金 需求，减持期间为2025年11月26日至2026年2月23日。上述股份来源于公司首次公开发行前取得的股 份。 ...